(Nasdaq:JAGX) Jaguar Health Inc Finished Up 25.84%


Jaguar Health Inc (Nasdaq:JAGX)

April 16th, 2019

With markets going up Jaguar Health Inc rose $0.06 Tuesday, up 25.84%, closing at $0.28. The stock continues to trade well at 133.33% of its 52 week low of $0.12. Two technical ‘scores’ for stocks to be aware of are the Altman Z1 and the Piotroski2 scores. JAGX scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is -4.71, and the Piotroski Score is 2).

Market Sectors

The market sectors were mixed Tuesday with a majority of the sectors trending up. Financials saw the biggest increase of the day (1.37%), while Real Estate saw the biggest drop (-2.38%). Information Technology has seen the biggest year-to-date gain at 23.78%.

Energy saw the biggest turnaround from its 5-day performance of -1.22%, as it went up 0.64%. Real Estate and Utilities experienced turn arounds from their five day positive performance, Real Estate with a drop of -2.38%.

Sector Breakdown

  • Financials went up with a 1.37% change.
  • Energy went up with a 0.64% change.
  • Industrials went up with a 0.59% change.
  • Information Technology went up with a 0.49% change.
  • Consumer Discretionary went up with a 0.48% change.
  • Materials went up with a 0.47% change.
  • Communication Services went up with a 0.21% change.
  • Consumer Staples went down with a -0.06% change.
  • Utilities went down with a -1.39% change.
  • Healthcare went down with a -2.03% change.
  • Real Estate went down with a -2.38% change.

Jaguar Health Inc Info

As of July 31, 2017, Jaguar Animal Health, Inc. was acquired by Napo Pharmaceuticals, Inc. in a reverse merger transaction. Jaguar Health, Inc., a natural-products pharmaceuticals company, focuses on developing and commercializing gastrointestinal products for human prescription use and animals worldwide. The company offers Mytesi, an antidiarrheal for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It also offers Canalevia, an animal prescription drug candidate used for the treatment of various forms of diarrhea in dogs; Equilevia, a non-prescription product for gut health in equine athletes; and Neonorm Calf and Neonorm Foal non-prescription animal products. The company was formerly known as Jaguar Animal Health, Inc. and changed its name to Jaguar Health, Inc. in July 2017. Jaguar Health, Inc. was founded in 2013 and is based in San Francisco, California.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Jaguar Health Inc’s score is -4.71) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Jaguar Health Inc’s score is 2), and 9 is the best.

JAGX daily update
JAGX daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.